We are live on ! Find out more
IBER

Ibere Pharmaceuticals
IBER

Delisted

IBER was delisted on the 1st of March, 2023.

Back to rankings

48 hedge funds and large institutions have $105M invested in Ibere Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 47 → 48 (+1)

5% more capital invested

Capital invested by funds: $99.8M → $105M (+$4.81M)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

Holders
48
Holders Change
+1
Holders Change %
+2.13%
% of All Funds
0.76%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
4
Reduced
7
Closed
6
Calls
$23K
Puts
–
Net Calls
+$23K
Net Calls Change
-$91K

Top Buyers

Rank Fund Capital Flow
1
KC
Kryger Capital
United Kingdom
+$4.11M
2
AC
Aristeia Capital
Connecticut
+$3.41M
3
Bank of America
Bank of America
North Carolina
+$3.12M
4
CCM
Context Capital Management
California
+$1.12M
5
SCM
Saba Capital Management
New York
+$779K

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.25M
2
MP
Mangrove Partners
Connecticut
-$1.94M
3
Wells Fargo
Wells Fargo
California
-$1.62M
4
SSA
Schonfeld Strategic Advisors
New York
-$1.31M
5
HIH
HRS Investment Holdings
New York
-$1.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
Brown Advisory
1
Brown Advisory
Maryland
$11.3M – – –
Citadel Advisors
2
Citadel Advisors
Florida
$7.63M +$8.42K +864 +0.1%
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
$6.05M – – –
Marshall Wace
4
Marshall Wace
United Kingdom
$5.22M +$7.79K +800 +0.2%
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$4.91M – – –
LA
6
Linden Advisors
New York
$4.41M – – –
Millennium Management
7
Millennium Management
New York
$4.33M -$31.9K -3,270 -0.7%
SC
8
Sculptor Capital
New York
$4.17M – – –
KC
9
Kryger Capital
United Kingdom
$4.14M +$4.11M +422,029 New
SCC
10
Spring Creek Capital
Kansas
$3.92M – – –
VI
11
Vestcor Inc
New Brunswick, Canada
$3.92M – – –
PC
12
Periscope Capital
Ontario, Canada
$3.48M +$731K +75,000 +27%
AC
13
Aristeia Capital
Connecticut
$3.43M +$3.41M +350,000 New
SCM
14
Shaolin Capital Management
Florida
$3.3M – – –
Bank of America
15
Bank of America
North Carolina
$3.14M +$3.12M +320,000 New
MCM
16
Moore Capital Management
New York
$2.94M – – –
RCM
17
Radcliffe Capital Management
Pennsylvania
$2.94M – – –
Nomura Holdings
18
Nomura Holdings
Japan
$2.77M – – –
CCA
19
Castle Creek Arbitrage
Colorado
$2.48M – – –
PMAM
20
Picton Mahoney Asset Management
Ontario, Canada
$1.96M – – –
GCL
21
Glazer Capital LLC
New York
$1.75M -$84K -8,622 -5%
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$1.7M -$2.25M -231,214 -57%
BCM
23
Basso Capital Management
Connecticut
$1.67M – – –
Alyeska Investment Group
24
Alyeska Investment Group
Illinois
$1.47M – – –
CCM
25
Context Capital Management
California
$1.13M +$1.12M +115,053 New
1
2 3

IBER Hedge Fund Activity: Q1 2022 in Review

48 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q1 2022, worth a combined $105M — up 4.8% from $99.8M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new IBER positions and 6 closed out — a net gain of 1 holder — while 4 added to existing stakes and 7 trimmed.

The largest buyer was Kryger Capital, opening a new position worth an estimated $4.11M. The largest seller was D.E. Shaw & Co, cutting an estimated $2.25M.

  • 48 institutional investors held Ibere Pharmaceuticals (IBER) as of Q1 2022, up from 47 in Q4 2021.
  • Funds reported $105M of Ibere Pharmaceuticals stock for Q1 2022, up 4.8% quarter-over-quarter.
  • 7 funds opened new Ibere Pharmaceuticals positions in Q1 2022 and 6 closed out, a net change of +1 holder.
  • The largest Ibere Pharmaceuticals buyer in Q1 2022 was Kryger Capital, an estimated $4.11M added.
  • The largest Ibere Pharmaceuticals seller in Q1 2022 was D.E. Shaw & Co, an estimated $2.25M sold.

Based on aggregated 13F filings for Q1 2022.